Joint research with the IMS Group on liquid biopsy and clinical applications
First written in FY2018-Q3. 9 of 10 entries say "Restated". Latest entry: FY2022-Q3.
1 other company's latest entry also says "Restated".
- FY2022-Q3RestatedAnnual report
「Following confirmation of the results of this joint research, liquid biopsy is scheduled to be applied clinically for cancer diagnosis at the IMS Group's medical institutions. CPM and the IMS Group's medical institutions will also continue to pursue broad partnerships in cancer precision medicine, including clinical sequencing for the genetic analysis of individual cancer patients.」
The joint research on liquid biopsy with the IMS Group, the planned clinical application following confirmation of the results, and the policy of pursuing broad partnerships remain ongoing. - FY2022-Q1RestatedAnnual report
「Following confirmation of the results of this joint research, liquid biopsy is scheduled to be applied clinically for cancer diagnosis at the IMS Group's medical institutions. CPM and the IMS Group's medical institutions will also continue to pursue broad partnerships in cancer precision medicine, including clinical sequencing for the genetic analysis of individual cancer patients.」
The joint research on liquid biopsy with the IMS Group, the planned clinical application following confirmation of the results, and the policy of pursuing broad partnerships remain ongoing. - FY2021-Q3RestatedAnnual report
「Following confirmation of the results of this joint research, liquid biopsy is scheduled to be applied clinically for cancer diagnosis at the IMS Group's medical institutions. CPM and the IMS Group's medical institutions will also continue to pursue broad partnerships in cancer precision medicine, including clinical sequencing for the genetic analysis of individual cancer patients.」
The joint research on liquid biopsy with the IMS Group, the planned clinical application following confirmation of the results, and the policy of pursuing broad partnerships remain ongoing. - FY2021-Q2RestatedAnnual report
「Following confirmation of the results of this joint research, we will pursue broad partnerships with Secom Medical System Co., Ltd. in cancer precision medicine, beginning with the adoption of liquid biopsy for cancer screening at Yotsuya Medical Cube.」
The existing joint research with the IMS Group, the planned clinical application following confirmation of the results, and the policy of pursuing broad partnerships remain ongoing. - FY2021-Q1RestatedAnnual report
「Following confirmation of the results of this joint research, liquid biopsy is scheduled to be applied clinically for cancer diagnosis at the IMS Group's medical institutions. CPM and the IMS Group's medical institutions will also continue to pursue broad partnerships in cancer precision medicine, including clinical sequencing for the genetic analysis of individual cancer patients.」
The joint research on liquid biopsy with the IMS Group, the planned clinical application following confirmation of the results, and the policy of pursuing broad partnerships remain ongoing. - FY2020-Q3RestatedAnnual report
「Following confirmation of the results of this joint research, liquid biopsy is scheduled to be applied clinically for cancer diagnosis at the IMS Group's medical institutions. CPM and the IMS Group's medical institutions will also continue to pursue broad partnerships in cancer precision medicine, including clinical sequencing for the genetic analysis of individual cancer patients.」
The joint research on liquid biopsy with the IMS Group, the planned clinical application following confirmation of the results, and the policy of pursuing broad partnerships remain ongoing. - FY2020-Q2RestatedAnnual report
「Following confirmation of the results of this joint research, liquid biopsy is scheduled to be applied clinically for cancer diagnosis at the IMS Group's medical institutions. CPM and the IMS Group's medical institutions will also continue to pursue broad partnerships in cancer precision medicine, including clinical sequencing for the genetic analysis of individual cancer patients.」
The joint research on liquid biopsy with the IMS Group, the planned clinical application following confirmation of the results, and the policy of pursuing broad partnerships remain ongoing. - FY2020-Q1RestatedAnnual report
「Following confirmation of the results of this joint research, liquid biopsy is scheduled to be applied clinically for cancer diagnosis at the IMS Group's medical institutions. CPM and the IMS Group's medical institutions will also continue to pursue broad partnerships in cancer precision medicine, including clinical sequencing for the genetic analysis of individual cancer patients.」
The joint research on liquid biopsy with the IMS Group, the planned clinical application following confirmation of the results, and the policy of pursuing broad partnerships remain ongoing. - FY2018RestatedAnnual report
「Following confirmation of the results of this joint research, liquid biopsy is scheduled to be applied clinically for cancer diagnosis at the IMS Group's medical institutions. CPM and the IMS Group's medical institutions will also continue to pursue broad partnerships in cancer precision medicine, including clinical sequencing for the genetic analysis of individual cancer patients.」
The joint research on liquid biopsy with the IMS Group and the planned clinical application following confirmation of the results remain ongoing. - FY2018-Q3First statedAnnual report
「CPM entered into a joint research agreement with the IMS Group (Meihokaikai Medical Corporation, Meirikai Medical Corporation and I'LL INC) to study methods for the early detection of residual cancer cells and recurrence after surgery for gastric and colorectal cancer using liquid biopsy (*).」
CPM entered into a joint research agreement with the IMS Group on liquid biopsy for the early detection of residual disease and recurrence after surgery for gastric and colorectal cancer. Following confirmation of the results, clinical application at the IMS Group's medical institutions is planned.